Insider · CIK 0001725722
AH Equity Partners Bio II, L.L.C.
Files at NAUT (Nautilus Biotechnology, Inc.), EQRX (EQRx, Inc.), SCTX (Scribe Therapeutics, Inc.). First filing Jun 4, 2026, latest Jun 4, 2026.
In brief
AH Equity Partners Bio II, L.L.C. files SEC Form 4 as 10% owner at NAUT (Nautilus Biotechnology, Inc.), and also at EQRX (EQRx, Inc.), SCTX (Scribe Therapeutics, Inc.). Since Jun 4, 2026, AH Equity Partners Bio II, L.L.C. has reported 0 open-market buys worth $0 and 1 open-market sell worth $12M, the latest filed on Jun 4, 2026.
A track record needs three past buys with six months of prices behind them; AH Equity Partners Bio II, L.L.C. has 0, so none is measured yet.
The newest scored trade: sold $12M of NAUT on Jun 2, 2026, filed Jun 4, 2026, scored 47 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $12M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NAUT: Nautilus Biotechnology, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 47Moderate | NAUTsell Nautilus Biotechnology, Inc. | $12M 5,000,000 shares | -31% | +319% from low-32% from high |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | NAUT Nautilus Biotechnology, Inc. | SOpen-market sale Common Stockindirect: By AH Bio Fund II, L.P. | -4,615,974 | $2.35 | $11M | 11,682,032 | Jun 4, 2026 |
| Jun 2, 2026 | NAUT Nautilus Biotechnology, Inc. | SOpen-market sale Common Stockindirect: By Andreessen Horowitz LSV Fund II, L.P. | -384,026 | $2.35 | $902k | 971,885 | Jun 4, 2026 |
| Nov 9, 2023 | EQRX EQRx, Inc. | UTender of shares Common Stockindirect: By AD Holdings, LLC | -12,264 | - | - | 0 | Nov 9, 2023 |
| Nov 9, 2023 | EQRX EQRx, Inc. | UTender of shares Common Stockindirect: By AH Bio Fund II, L.P. | -17,438,465 | - | - | 0 | Nov 9, 2023 |
| Nov 9, 2023 | EQRX EQRx, Inc. | UTender of shares Common Stockindirect: By AH Bio Fund III, L.P. | -19,192,015 | - | - | 0 | Nov 9, 2023 |
| Nov 9, 2023 | EQRX EQRx, Inc. | UTender of shares Common Stockindirect: By Andreessen Horowitz LSV Fund I, L.P. | -11,433,677 | - | - | 0 | Nov 9, 2023 |
| Nov 9, 2023 | EQRX EQRx, Inc. | UTender of shares Common Stockindirect: By Andreessen Horowitz LSV Fund II, L.P. | -5,000,000 | - | - | 0 | Nov 9, 2023 |
| Nov 9, 2023 | EQRX EQRx, Inc. | UTender of shares Earn-out Sharesderivativeindirect: By AH Bio Fund II, L.P. | -2,401,418 | - | - | 0 | Nov 9, 2023 |
| Nov 9, 2023 | EQRX EQRx, Inc. | UTender of shares Earn-out Sharesderivativeindirect: By AH Bio Fund III, L.P. | -2,642,897 | - | - | 0 | Nov 9, 2023 |
| Nov 9, 2023 | EQRX EQRx, Inc. | UTender of shares Earn-out Sharesderivativeindirect: By Andreessen Horowitz LSV Fund I, L.P. | -1,574,510 | - | - | 0 | Nov 9, 2023 |
Questions about AH Equity Partners Bio II, L.L.C.
Answered from the filings on this page, as of the latest one.
Is AH Equity Partners Bio II, L.L.C. buying or selling?
In the last 12 months AH Equity Partners Bio II, L.L.C. reported 0 open-market buys worth $0 and 1 open-market sell worth $12M on SEC Form 4; the latest was sold $12M of NAUT on Jun 2, 2026. Grants, option exercises and tax withholding are not counted.
How did AH Equity Partners Bio II, L.L.C.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and AH Equity Partners Bio II, L.L.C. has 0.
Where does AH Equity Partners Bio II, L.L.C. file Form 4?
AH Equity Partners Bio II, L.L.C. has filed Form 4 at NAUT (Nautilus Biotechnology, Inc.); EQRX (EQRx, Inc.); SCTX (Scribe Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.